Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition

The mechanism of topoisomerase I poisoning by a camptothecin analog

Bart L. Staker, Kathryn A. Hjerrild, M.D. Feese et al. · Proceedings of the National Academy of Sciences · 2002 · 802 citations · Full text

Medicine, Oncology, Pharmacology +14

Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I−DNA Covalent Complex

Bart L. Staker, M.D. Feese, Mark Cushman et al. · Journal of Medicinal Chemistry · 2005 · 535 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +16

Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide

Chyuan-Chuan Wu, Tsai‐Kun Li, Lynn Farh et al. · Science · 2011 · 514 citations

Life Sciences, Molecular Biology, Oncology +14

Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies

Anna M. Azarova, Yi Lisa Lyu, Chao‐Po Lin et al. · Proceedings of the National Academy of Sciences · 2007 · 290 citations · Full text

Medicine, Oncology, Pharmacology +16

Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells

Fei Shen, Shaoyou Chu, Aimee K. Bence et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 264 citations

Medicine, Oncology, Pharmacology +16